StiL NHL7 MAINTAIN results shed light on B-R upfront and R-maintenance

Mathias Rummel, MD, PhD, Justus Liebig University, Giessen, Germany, discusses the results of a prospective, randomized, multicenter phase III study. The StiL NHL7-2008 MAINTAIN trial (NCT00877214) compared the effect of 2 years rituximab (R-)maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with previously untreated Waldenström's macroglobulinemia (WM). The data confirmed that induction with B-R is highly effective in this setting, with no statistically significant improvement in PFS or OS after a 2-year R-maintenance compared with observation after B-R induction in patients with WM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Speaker: Mathias Rummel,Event: ASH 2019,Format: Interview,Subject: Waldenström’s Macroglobulinemia,Subject: Non-Hodgkin Lymphoma,Subject: B-Cell Lymphoma,Field: Trial Updates,highlights,Trial: StiL NHL7-2008 MAINTAIN,Field: Treatment,Medicines: Rituximab,Medicines: Ibrutinib,Field: Immuno-Oncology,Medicines: Antibodies,Medicines: Bendamustine,PFS,maintenance,NCT00877214,